Spero Therapeutics (SPRO) Return on Capital Employed (2017 - 2026)
Spero Therapeutics' (SPRO) quarterly Return on Capital Employed came in at 20.35% in Q1 2026, up 13263.0% YoY from N/an in Q1 2025, and up 127.78% on a QoQ basis from 8.93% in Q4 2025.
Spero Therapeutics (SPRO) Return on Capital Employed (2017 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 10 years of Return on Capital Employed data on file, last reported at 20.35% in Q1 2026.
- Quarterly Return on Capital Employed rose 13263.0% year-over-year to 20.35% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 20.35% (up 13263.0% YoY) and the FY2025 annual result came in at 7.81%, up 8313.0% from the prior year.
- Return on Capital Employed rose to 20.35% in Q1 2026, from 8.93% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 20.35% in Q1 2026 to a low of 199.94% in Q3 2022.
- A 5-year average of 52.95% and a median of 31.81% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 13094 bps — and 2023, when it soared 19046 bps.
- Tracing SPRO's Return on Capital Employed over 5 years: stood at 63.59% in 2022, then soared by 127 bps to 17.29% in 2023, then slumped by 666 bps to 97.87% in 2024, then surged by 109 bps to 8.93% in 2025, then soared by 128 bps to 20.35% in 2026.
- The last three Return on Capital Employed figures came in at 20.35% (Q1 2026), 8.93% (Q4 2025), and 104.02% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.50 Bn | 131.65 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.10 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 65.59 Bn | 60.41 Bn | 1.37 Bn | - |
| 4 | Moderna | 56.75 Bn | 51.62 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.64 Bn | 28.33 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 27.80 Bn | 9.41 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 7.88% |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - | 12.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.00% |
| Mar 31, 2026 | 20.35% |
| Dec 31, 2025 | 8.93% |
| Sep 30, 2025 | -104.02% |
| Jun 30, 2025 | -102.49% |
| Mar 31, 2025 | -112.29% |
| Dec 31, 2024 | -97.87% |
| Sep 30, 2024 | -3.02% |
| Jun 30, 2024 | 11.20% |
| Mar 31, 2024 | 14.15% |
| Dec 31, 2023 | 17.29% |
| Sep 30, 2023 | -9.47% |
| Jun 30, 2023 | -19.51% |
| Mar 31, 2023 | -31.81% |
| Dec 31, 2022 | -63.59% |
| Sep 30, 2022 | -199.94% |
| Jun 30, 2022 | -117.47% |
| Mar 31, 2022 | -110.67% |
| Dec 31, 2021 | -63.19% |
| Sep 30, 2021 | -69.00% |